FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Multiple sclerosis: Closing in on an oral treatment

(2010) Roland Martin   NATURE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis

(2009) Masaru Ishii et al.   NATURE

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors

(2009) Florian Mullershausen et al.   Nature Chemical Biology

A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis

(2008) David Wheeler et al.   BRAIN

Astrocytes in multiple sclerosis: A product of their environment

(2008) A. Nair et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease

(2008) Yun-Ping Wu et al.   HUMAN MOLECULAR GENETICS

Central nervous system-directed effects of FTY720 (fingolimod)

(2008) Veronique E. Miron et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets

(2008) May H. Han et al.   NATURE